Entera Bio Ltd (ENTX) - Total Liabilities
Based on the latest financial reports, Entera Bio Ltd (ENTX) has total liabilities worth $2.17 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Entera Bio Ltd to track the company's year-over-year net asset growth rate.
Entera Bio Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's total liabilities have evolved over time, based on quarterly financial data.
Entera Bio Ltd Competitors by Total Liabilities
The table below lists competitors of Entera Bio Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dynamic Medical Technologies
TWO:4138
|
Taiwan | NT$1.23 Billion |
|
Solutions 30 SE
F:30L3
|
Germany | €624.50 Million |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
India | Rs385.53 Billion |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
Turkey | TL1.27 Billion |
|
Clene Inc.
NASDAQ:CLNN
|
USA | $40.47 Million |
|
HLB Life Science Co. Ltd
KQ:067630
|
Korea | ₩173.00 Billion |
|
Castellum Inc.
NYSE MKT:CTM
|
USA | $5.68 Million |
|
EuroDry Ltd
NASDAQ:EDRY
|
USA | $109.59 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Entera Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Entera Bio Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entera Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entera Bio Ltd (2015–2024)
The table below shows the annual total liabilities of Entera Bio Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.31 Million | -5.00% |
| 2023-12-31 | $1.38 Million | +0.44% |
| 2022-12-31 | $1.37 Million | -59.88% |
| 2021-12-31 | $3.42 Million | +54.70% |
| 2020-12-31 | $2.21 Million | -53.76% |
| 2019-12-31 | $4.78 Million | +48.34% |
| 2018-12-31 | $3.23 Million | -92.81% |
| 2017-12-31 | $44.84 Million | +42.19% |
| 2016-12-31 | $31.53 Million | +10.90% |
| 2015-12-31 | $28.43 Million | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more